



1. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-Term Outcome and Prognostic Factors of Juvenile Dermatomyositis : A Multinational , Multicenter Study of 490 Patients. 2010;62:63–72.
2. Hospital J. Disease Patterns of Juvenile Dermatomyositis From Western India. 2013;2:15–7.
3. Twilt M. An update on the diagnosis and management of juvenile dermatomyositis R eview. 2012;7:325–33.
4. Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76:329–40.
5. Rosa Neto NS, Goldenstein-Schainberg C. Juvenile dermatomyositis: review and update of the pathogenesis and treatment. Rev Bras Reumatol. 2010;50:299–312.
6. Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol. 2009;23:665–78.
7. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic infl ammatory myopathies of childhood. 2008;2201–12.
8. Sanner H. Outcomes and prognostic factors in Juvenile Dermatomyositis Doctoral thesis by. 2010.
9. Hanlon TPO, Li Z, Gan L, Gourley MF, Rider LG, Miller FW. Plasma proteomic profiles from disease- discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases *. 2011;
10. Mccann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)— clinical characteristics of children recruited within the first 5 yr. 2018;1255–60.
11. Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, et al. Damage Extent and Predictors in Adult and Juvenile Dermatomyositis and Polymyositis Using the Myositis Damage Index. 2010;60:3425–35.
12. Symmons DPM, Sillst JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. 1995;732–6.
13. Huber A, Feldman BM. Long-term Outcomes in Juvenile Dermatomyositis : How Did We Get Here and Where Are We Going ? 2005;



14. Bode RK, Klein-gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease Activity Score for Children With Juvenile Dermatomyositis : Reliability and Validity Evidence. 2003;49:7–15.
15. Callen JP, Wortmann RL. Dermatomyositis. 2006;363–73.
16. Chari G, Laude TA. Juvenile Dermatomyositis : A Review. 2000;15:21–5.
17. Polychronopoulou T. Physiotherapy in Juvenile Dermatomyositis. J Res Pract Musculoskelet Syst. 2017;1:14–8.
18. Pachman LM, Liotta-davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, et al. TNF α -308A ALLELE IN JUVENILE DERMATOMYOSITIS Association with Increased Production of Tumor Necrosis Factor α , Disease Duration , and Pathologic Calcifications. 2000;43:2368–77.
19. Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatol (United Kingdom). 2014;53:2204–8.
20. Elzouki A, Harfi H, Stapleton F WR. Juvenile dermatomyositis. Textbook of Clinical Pediatrics.
21. Patwardhan A, Rennebohm R, Dvorchik I, Spencer CH. Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience. Pediatr Rheumatol. 2012;10:1–12.
22. Gradwohl-Matis I, Illig R, Salmhofer H, Neureiter D, Brunauer A, Dünser MW. Fulminant systemic capillary leak syndrome due to C1 inhibitor deficiency complicating acute dermatomyositis: A case report. J Med Case Rep. 2014;8:2–5.
23. Willenberg T, Diehm N, Zwahlen M, Kalka C, Do D, Gretener S, et al. Impact of Long-term Corticosteroid Therapy on the Distribution Pattern of Lower Limb Atherosclerosis. Eur J Vasc Endovasc Surg. 2010;39:441–6.
24. Ong SLH, Zhang Y, Whitworth JA. Mechanisms of Dexamethasone-Induced Hypertension. 2009;
25. Kumara DK, Suarta K, Soetjningsih. Tinggi Badan dan Usia Tulang Sindrom Nefrotik yang Mendapat Terapi Steroid Jangka Panjang. 2002;4:83–7.
26. Klaus G, Jux C, Fernandez P, Rodriguez J, Himmele R, Mehls O. Suppression of growth

- plate chondrocyte proliferation by corticosteroids. 2000;612–5.
27. Hattori T, Murase T, Iwase E, Takahashi K, Ohtake M, Tsuboi K, et al. Glucocorticoid-Induced Hypertension and Cardiac Injury: Effect of Mineralcorticoid and Glucocorticoid Receptor Antagonism. 2013;81–92.
 28. Guern V Le, Guettrot-imbert G, Costedoat-chalumeau N. Hydroxychloroquine: A multifaceted treatment in lupus. *Presse Med.* 2014;
 29. Dervisoglou T, Matiakis A. Oral Ulceration Due to Methotrexate Treatment : A Report of 3 Cases and Literature Review. 2015;
 30. Lim AYN, Gaffney K, Scott DGI. Methotrexate-induced pancytopenia : serious and under-reported ? Our experience of 25 cases in 5 years. 2005;1051–5.
 31. Chan ESL, Cronstein BN. Mechanisms of Action of Methotrexate. 2013;71:5–8.
 32. Ba BDJ, Frcpc AD, Frcpc PMW, Frcpc NHS, Jakubovic BD, Donovan A, et al. Methotrexate induced pulmonary toxicity. 2013;20:153–5.
 33. Buhroo AM, Ortho MS. Adverse Effects of Low-Dose Methotrexate in Patients with Rheumatoid Arthritis. 2012;
 34. Hansen MS, Schuman SG. Hydroxychloroquine-Induced Retinal Toxicity. :33–5.
 35. Sawalha H. Hydroxychloroquine induced Hyperpigmentation of the Skin. 2015;42:1–3.
 36. Ross E Petty, Ronald M. Laxer, Carol B Lindsley LW. Text book of pediatric rheumatology: Juvenile dermatomyositis. 7th editio. Elsevier; 2016. 360-381 hal.
 37. Sjarif DR, Lestari ED, Mexitalia M, Nasar SS. Buku ajar nutrisi pediatrik dan penyakit metabolik: Obesitas. 1st ed. Jakarta: Penerbit IDAI; 2014. 236-251 hal.
 38. Lestari N, Nurani N, Julia M. Corticosteroids and obesity in steroid-sensitive and steroid-resistant nephrotic syndrome. *Paediatr Indones.* 2015;55:194–8.
 39. Wang M. The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. *Nutr Metab.* 2005;2:1–14.
 40. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy, Asthma, Clin Immunol.* 2013;9:1–25.
 41. Briot K, Roux C. Glucocorticoid-induced osteoporosis. *RMD Open.* 2015;1.
 42. Fraser L-A, Adachi JD. Glucocorticoid-induced osteoporosis: treatment update and review. *Ther Adv Musculoskelet Dis.* 2009;1:71–85.



UNIVERSITAS
GADJAH MADA

JUVENILE DERMATOMYOSITIS

ANINDITYA DWI M, dr. Endy Paryanto Prawirohartono, MPH., Sp.A(K); dr. Sumadiono, Sp.A(K)

Universitas Gadjah Mada, 2019 | Diunduh dari <http://etd.repository.ugm.ac.id/>